ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM
Abstract Number: 2290
Association of Mycophenolate and Azathioprine Use with Cognitive Function in Systemic Lupus Using a Bayesian Longitudinal Item-response Theory Model
(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III
9:00AM-11:00AM
Abstract Number: 1799
Association of Pregabalin vs Gabapentin with Incident Congestive Heart Failure in Patients with Non-Cancer Pain
(1796–1826) Epidemiology & Public Health Poster III
9:00AM-11:00AM
Abstract Number: 2194
Association of Self-perceived Oral Health Status with ESSPRI Reported by Sjögren’s Syndrome Patients
(2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II
9:00AM-11:00AM
Abstract Number: 2222
Association Spondyloarthritis and Inflammatory Bowel Disease, More Severe Diseases on Both Sides
(2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA
9:00AM-11:00AM
Abstract Number: 2127
Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer
(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III
9:00AM-11:00AM
Abstract Number: 2139
Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort
(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III
9:00AM-11:00AM
Abstract Number: 1763
Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up
(1734–1775) RA – Etiology and Pathogenesis Poster
9:00AM-11:00AM
Abstract Number: 2070
Augmenting Medical Education: An Evaluation of GPT-4 and ChatGPT in Answering Rheumatology Questions from the Spanish Medical Licensing Examination
(2061–2088) Professional Education Poster
9:00AM-11:00AM
Abstract Number: 2134
Autoantibodies to Joint-related Proteins Predict Remission with High Specificity in New Onset RA
(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III
9:00AM-11:00AM
Abstract Number: 1706
Autoreactive B Cell Responses Are Enriched in Early-onset Oligoarticular Juvenile Idiopathic Arthritis
(1705–1712) Pediatric Rheumatology – Basic Science Poster
9:00AM-11:00AM
Abstract Number: 2208
Awareness and Attitudes Regarding Axial Spondyloarthritis Among Non-Rheumatology Physicians in the United States
(2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA
9:00AM-11:00AM
Abstract Number: 2010
B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort
(1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster
9:00AM-11:00AM
Abstract Number: 2021
Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy
(2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III
9:00AM-11:00AM
Abstract Number: 2250
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
(2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III
9:00AM-11:00AM
Abstract Number: 2252
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
(2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III
  • «Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 59
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology